Artificial intelligence in Cancer Clinical Research: IV. Inherent Limitations of Artificial Intelligence.
Publication
, Journal Article
Lyman, GH; Kuderer, NM
Published in: Cancer Invest
October 2024
Duke Scholars
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
October 2024
Volume
42
Issue
9
Start / End Page
741 / 744
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., & Kuderer, N. M. (2024). Artificial intelligence in Cancer Clinical Research: IV. Inherent Limitations of Artificial Intelligence. Cancer Invest, 42(9), 741–744. https://doi.org/10.1080/07357907.2024.2412449
Lyman, Gary H., and Nicole M. Kuderer. “Artificial intelligence in Cancer Clinical Research: IV. Inherent Limitations of Artificial Intelligence.” Cancer Invest 42, no. 9 (October 2024): 741–44. https://doi.org/10.1080/07357907.2024.2412449.
Lyman GH, Kuderer NM. Artificial intelligence in Cancer Clinical Research: IV. Inherent Limitations of Artificial Intelligence. Cancer Invest. 2024 Oct;42(9):741–4.
Lyman, Gary H., and Nicole M. Kuderer. “Artificial intelligence in Cancer Clinical Research: IV. Inherent Limitations of Artificial Intelligence.” Cancer Invest, vol. 42, no. 9, Oct. 2024, pp. 741–44. Pubmed, doi:10.1080/07357907.2024.2412449.
Lyman GH, Kuderer NM. Artificial intelligence in Cancer Clinical Research: IV. Inherent Limitations of Artificial Intelligence. Cancer Invest. 2024 Oct;42(9):741–744.
Published In
Cancer Invest
DOI
EISSN
1532-4192
Publication Date
October 2024
Volume
42
Issue
9
Start / End Page
741 / 744
Location
England
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis